BRIEF-Denali Therapeutics Says Co Prices Public Offering Of 9.14 Mln Shares At $17.50 Each

Denali Therapeutics Inc - Prices Public Offering of 9,142,857 Shares at $17.50 Each

BRIEF-Kymera Therapeutics Announces Pricing Of Upsized $602 Million Public Offering At $86 Per Share

Kymera Therapeutics Inc - Selling 7,000,000 Shares at $86 per Share

Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

Opus Genetics Inc : B. Riley Initiates Coverage With Buy Rating; Price Target $9

BRIEF-Dyne Therapeutics Says Co Prices Public Offering At $18.44 Per Share

Dyne Therapeutics Inc - Public Offering Priced at $18.44 per Share, $350 Mln Expected Proceeds

Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock

BRIEF-Vera Therapeutics Prices Public Offering Of Class A Common Stock At $42.50 Per Share

Vera Therapeutics Inc - Prices Public Offering at $42.50 per Share

Vera Therapeutics Announces Pricing of Public Offering of Class a Common Stock

Director Rowan E. Chapman Reports Disposal of Natera Inc. Common Shares

Xenon Pharmaceuticals CEO Ian Mortimer Reports Disposal of Common Shares

Centessa Pharmaceuticals President Mario Alberto Accardi Reports Disposal of Common Shares

Biomea Fusion Highlights Icovamenib Data at WCIRDC 2025

First Case of Staggered Payment in M&A Consideration Approved by SSE's Restructuring Committee

Director Michael S. Perry Reports Sale of Arrowhead Pharmaceuticals Common Shares